Please login to the form below

Not currently logged in
Email:
Password:

J&J's Prezista wallops Abbott's Kaletra

Johnson & Johnson's Prezista beats Abbott's protease inhibitor Kaletra in controlling HIV replication in a head-to-head clinical trial

US-headquartered Johnson & Johnson's Prezista (darunavir) has beaten Abbott's Kaletra (lopinavir) in controlling HIV replication in a head-to-head clinical trial.

In the trial, both protease-inhibitor drugs were boosted with doses of ritonavir and taken by patients who had previously been using other drugs to control HIV infection, which leads to AIDS.

The data was presented at the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Sydney. The team, led by Jose Valdez-Madruga, demonstrated that after 48 weeks of treatment, 71 per cent of HIV-infected participants who took darunavir had undetectable viral loads. Only 60 per cent of patients on lopinavir achieved undetectable levels of the virus.

The primary endpoint of the trial was to show there were no differences in outcomes, but Valdez-Madruga said he found superiority with darunavir, developed by J&J's Belgium-based subsidiary Tibotec.

Valdez-Madruga, who is director of clinical trials for the Sao Paulo AIDS Programme in Brazil was reported as saying: "This is the first time that any drug has been shown to be superior to lopinavir. Patients with experienced HIV infection now have an option for treatment."

He added that his team also found that darunavir appears to protect the other drugs classes better than lopinavir. Also, fewer resistance mutations in the nucleoside reverse transcriptase class and in the protease inhibitor class appeared while patients were being treated with darunavir.

In Q2 FY07, Abbott posted global Kaletra sales of USD 315m, up 18.9 per cent on Q2 FY06 revenues. For H1 FY07, sales of Kaletra were USD 615m, up 12.9 per cent on H1 FY06.

Analysts have estimated that peak sales of Prezista may reach USD 900m a year. The drug currently has a wholesale cost of USD 25 per day.

26th July 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

segmentation_pie_thumb.jpg
If you’re not thinking segmentation, you’re not thinking
Having a background in market research I’ve been lucky to work on a number of customer segmentations in my time but working in creative communications it is still too rare...
Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
The 16th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD)conference took place at the Hilton Madrid Airport hotel on 15–16 May 2018....
Londonvelophobia (fear of cycling in London) – debunked
...

Infographics